LEIDOS BIOMEDICAL RESEARCH, INC.
EVALUATION OF IVO COMPOUNDS IN BLEOMYCIN-INDUCED PULMONARY FIBROSIS MODEL
EVALUATION OF IVO COMPOUNDS IN BLEOMYCIN-INDUCED PULMONARY FIBROSIS MODEL is a funding opportunity from LEIDOS BIOMEDICAL RESEARCH, INC., up to 219752, closing September 14, 2027.
Sep 14, 2027
(410d left)Overview
To evaluate the efficacy of IVO compounds, the bleomycin-induced pulmonary fibrosis model in C57BL/6J mice, the most well-characterized and widely used preclinical model of IPF, will be used. Bleomycin administration results in reproducible pulmonary inflammation followed by fibrotic remodeling, leading to functional…